武清区龙济生殖泌尿科(天津武清区龙济男科医院正规吗) (今日更新中)

HONG KONG, March 18 (Xinhua) -- After over a year's efforts, scientists from Shanghai and Hong Kong announced on Friday that they have completed the whole genomic sequencing work of Isaria cicada, a rare herb highly valued in traditional Chinese medicine, which will help facilitate its further development in medical and nutrition fields.It is the first time that the whole genomic sequence of Isaria cicada has been released, said the scientists from Shanghai Institute of Bio-Asia Life Science and the Hong Kong University of Science and Technology (HKUST), who participated in the research.The result was announced at the International Biomedical Scientists and Biotechnology Forum 2011 held in the day at the Hong Kong Science Park.According to the result, the genomic size of Isaria cicada, a medicine traditionally used to treat children's diseases, is about one eightieth of human genome, containing about 16,000 genes.The tests that had been done proved that Isaria cicada, with many high-quality genes not recognized or used by human beings yet, has been deeply involved in important life processes like metabolism, providing new ways for further development of Isaria cicad in bio-medical area, said a scientist from HKUST.The genome map will also help accelerate the artificial cultivation of Isaria cicada, enhancing its medicine and nutrition value and making it available in a larger market, according to the scientist.

LOS ANGELES, April 7 (Xinhua) -- A new research has found that about nine million people in the United States identify themselves as lesbian, gay, bisexual or transgender (LGBT).About 1.8 percent of adults identify themselves as bisexual, 1. 7 percent as gay or lesbian, and 0.03 percent as transgender, researchers at the University of California-Los Angeles' School of Law said in the study published by The Los Angeles Times on Thursday.The study culled data and methods from nine surveys conducted over the last seven years and averaged results from five of those surveys to estimate sexual orientation and from two surveys to estimate the transgender population.The findings also show that about 8.2 percent of Americans said they participated in same-sex sexual activity and about 11 percent said they had some same-sex sexual attraction, but neither of these groups necessarily identified themselves as LGBT.The researchers noted that insufficient and inconsistent national surveys make it difficult to get an estimate of the LGBT population in the United States, according to the Times report.

BEIJING, May 24 (Xinhuanet) -- CT scan, a widely used heart-imaging test, is likely to result in the over treatment for patients with heart disease, according to a study published online by the Archives of Internal Medicine on Monday.CT, which produces a detailed image of the heart that reveals cholesterol buildups in the coronary arteries, is widely used in the hospital around the world."Testing might lead to more harm than good," said McEvoy, a doctor at Seoul National University Bundang Hospital in S. Korea.His team led the study, in which 2,000 healthy adults were divided into two groups. One thousand adults had CT scans and another half had standard tests, including routine checks of their blood pressure and cholesterol levels.After 18 months, the 215 people who had worrisome CT scans were advised to have additional tests and medical treatment, and some even advised to have surgery. But less than 10 percent in the group of standard test were reported to need medications.Therefore, physicians cannot easily ignore the diagnoses made by the new imaging techniques, McEvoy said, "We are left with the dilemma of what to do with the results,"According to McEvoy, doctors should focus on patients' lifestyle and traditional risk factors such as smoking and obesity.

ABU DHABI, Feb. 10 (Xinhua) -- China believes that Egypt has sufficient wisdom and capability to overcome difficulties and realize national stability and development, visiting Chinese Foreign Minister Yang Jiechi told his Egyptian counterpart in a telephone conversation Thursday.Yang, who was on a visit to the United Arab Emirates (UAE), told the Egyptian Foreign Minister Ahmed Abul Gheit that China pays close attention to the situation in Egypt, adding that Egypt, as an influential country in the Middle East, is vital to the region's stability.Egypt's internal affairs should be resolved by Egyptians themselves and should be free of outside interference, he added.Gheit briefed Yang on Egypt's situation, saying his government was taking measures to safeguard social stability and return the country to normality.Both sides also expressed satisfaction with the development of China-Egypt relations in the past year, saying the strategic cooperation between the two countries has great potential and broad development prospects.Yang arrived in the UAE capital of Abu Dhabi late Wednesday for an official visit to the Gulf nation.

WASHINGTON, May 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Sutent to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body.Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer than 1,000 new cases in the United States each year.This is the second new approval by the FDA to treat patients with this disease. On May 5, the agency approved Afinitor."FDA believes it is important to provide cancer patients with as many treatment options as possible," said Richard Pazdur, director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "The agency is committed to working with companies to bring innovative new therapies to the market and encourages companies to continue exploring additional uses for approved products."The safety and effectiveness of Sutent was established in a single study of 171 patients with metastatic (late-stage) or locally advanced (disease that could not be removed with surgery) disease who received Sutent or a placebo (sugar pill). The study was designed to measure the length of time a patient lived before their disease spread or worsened (progression-free survival).Results from the study demonstrate that Sutent provided benefit to patients by prolonging the median length of time they lived without the cancer spreading or worsening to 10.2 months compared to 5.4 months for patients who received placebo.In patients treated with Sutent for neuroendocrine pancreatic tumors, the most commonly reported side effects included diarrhea, nausea, vomiting, fatigue, anorexia, high blood pressure, energy loss, stomach pain, changes in hair color, inflammation of the mouth, and a decrease in infection-fighting white blood cells.Sutent is marketed by New York City-based Pfizer.

来源：资阳报